Changyun Hu | CSO & Co-Founder
Adept Therapeutics Inc

Changyun (Eric) Hu is CSO of Adept Therapeutics Inc, a biotech company focusing on developing antibody-mediated immunotherapies for cancer patients. Changyun's effort has contributed to several patents and multiple IND filings and is known for his expertise in antibody drug discovery against multi-transmembrane targets such as GPCRs. He discovered an anti-CCR8 antagonist antibody that was licensed to Gilead Science Inc for clinical development. And he was one of the first few that discovered the regulatory role of B cells in autoimmune setting. He has established a track record in the scientific community with 20+ peer-reviewed highly-cited publications and presentations at national and international conferences. Changyun holds a PhD and is a seasoned drug hunter with extensive experience from target identification and validation, antibody discovery and optimization, to IND filing.